The ‘symptomatic vs curative’ distinction might take care of this apparent contradiction—those trillions of dollars are going towards the former (i.e. the diseases and disabilities of aging), while a vanishingly small fraction in comparison goes towards the latter (e.g. senescence research).
The ‘symptomatic vs curative’ distinction might take care of this apparent contradiction—those trillions of dollars are going towards the former (i.e. the diseases and disabilities of aging), while a vanishingly small fraction in comparison goes towards the latter (e.g. senescence research).